ArticleFrontiers in rehabilitation sciences2025
Case Report: Focused shockwave therapy (fESWT) in thumb carpometacarpal joint osteoarthritis: a single case study.
Article in Frontiers in rehabilitation sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Several studies have demonstrated the efficacy of shock wave therapy in managing OA-related pain and improving joint function but evidence specific to thumb CMC joint OA remains limited. Therefore, the aim of this study was to evaluate the effectiveness of fESWT in reducing pain and improving function as well as to assess the safety and tolerability of this intervention, providing insight into its potential role as a non-invasive and long-term alternative for patients unresponsive to conventional therapies or seeking to avoid surgery. Methods: A 64-year-old woman with radiographically confirmed bilateral CMC OA and persistent symptoms unresponsive to prior conservative treatments received three weekly fESWT sessions. Energy flux density was individually adjusted per session based on tolerance. Outcome measures included the QuickDASH questionnaire and grip strength testing, assessed at baseline, 2-, 8-, 26-, and 52-weeks post-intervention. Results: Treatment was well tolerated with no adverse events. QuickDASH scores improved from 20.5 at baseline to 2.3 at 52 weeks, indicating an improvement in pain and functional disability. Grip strength increased by 29.5% in the right hand and 17.4% in the left hand over the same period. Subjectively, the patient reported pain relief, functional improvement, and sustained benefit at one-year follow-up. Conclusions: This case demonstrates the potential of individualized fESWT as a safe and effective intervention for thumb CMC OA, with improvements in pain and function lasting up to 12 months. These findings support further investigation of fESWT in larger controlled studies and highlight the importance of individualized dosing strategies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.